MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report
MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report
NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its second quarter 2024 financial results before the market opens on August 13, 2024. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update.
2024年8月1日,纳斯达克上市公司MiNk Therapeutics, Inc.(股票代码:INKT)是一家临床阶段的生物制药公司,致力于发现、开发和商业化全异基因、即插即用的不变式自然杀伤T(iNKT)细胞治疗癌症和其他免疫介导性疾病。公司将于2024年8月13日市场开盘前发布2024年第二季度财务业绩。当天上午8:30,MiNk的高管将主持电话会议和网络直播,讨论业绩并提供公司的更新。
Conference Call
电话会议
Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada)
拨入电话号码:646-307-1963(纽约),800-715-9871(美国和加拿大)
Conference ID: 4021545
会议ID:4021545
Webcast
网络转播
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company's website at and via .
公司网站的“活动和展示”页面和.链接可访问会议的网络直播和回放。
About MiNK Therapeutics
MiNK Therapeutics简介
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
MiNk Therapeutics 是一家临床中期的生物制药公司,开创性地开发和商业化异基因、现成的不变自然杀伤T(iNKT)细胞治疗癌症和其他免疫介导性疾病。MiNk正在推进一系列原生和下一代工程 iNKt 计划,旨在为现成交付提供可扩展和可再现制造的平台。该公司总部位于纽约,NY。更多信息,请访问或关注@MiNK_iNKt。与投资者有关的可能重要信息将定期发布在我们的网站和社交媒体渠道上。
Investor Contact
投资者联系方式
917-362-1370
917-362-1370
investor@minktherapeutics.com
investor@minktherapeutics.com
Media Contact
媒体联系人
781-674-4428
781-674-4428
communications@minktherapeutics.com
communications@minktherapeutics.com
Source: MiNK Therapeutics
来源:MiNK治疗